CME/CE

This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.

This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.

This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.

This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.

This program explores evolving strategies for low-density lipoprotein cholesterol (LDL-C) management in patients at high cardiovascular (CV) risk who have not yet experienced a myocardial infarction or stroke. Drs. Bohula and Leiter discuss unmet needs, shifting LDL-C targets, and emerging treatment strategies, including PCSK9 inhibitors and results from the VESALIUS-CV trial. The conversation highlights how early, intensive LDL reduction can meaningfully lower the risk of first CV events. Practical guidance is shared on risk assessment, statin optimization, evaluating and managing statin intolerance, and the use of combination lipid-lowering therapy.

On-demand webcast on the latest advances in diagnosing and managing patients with IgA nephropathy (IgAN), including the current data on new and emerging IgAN therapies.

On-demand webcast on the role of interleukin (IL)-13 in atopic dermatitis pathophysiology and strategies for leveraging IL-13 inhibitors to address disease burden and improve patient outcomes.

In this on-demand webcast, leading experts in brain health provide guidance for patient education, discussion, and management geared toward HCPs in primary care who are at the forefront of an aging population at risk of cognitive decline trying to plan for its future and for whom brain health is a topic of uttermost importance.

On-demand webcast on the latest advances in diagnosing and managing patients with eosinophilic granulomatosis with polyangiitis (EGPA), including current data on new EGPA therapies and shared decision-making strategies to help patients achieve and maintain remission.

This podcast reviews the International Psoriasis Council (IPC) 2025 guidance on reclassifying psoriasis severity and redefining failure of topical therapies. Clinical features such as high-impact disease sites, failure of topical treatment, or BSA >10% all factor into whether patients are candidates for systemic therapy in this new guidance. Despite broad endorsement, many clinicians remain uncertain about applying the new framework. This activity aims to raise awareness, clarify updated criteria, and align practice with current evidence supporting earlier use of IL-23 and IL-17 inhibitors in appropriate patients.